Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis

Arthritis and Rheumatism

Volumn 46, Issue 10, 2002, Pages 2765-2775

  Getting, Stephen J ^a   Christian, Helen C ^b   Flower, Roderick J ^a   Perretti, Mauro ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CORTICOSTERONE; CORTICOTROPIN; CYCLIC AMP; CYTOKINE; DEXAMETHASONE; INDOMETACIN; INTERMEDIN; MELANOCORTIN 3 RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; URATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE EXPRESSION; GOUT; HUMAN; HUMAN CELL; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ARTHRITIS, GOUTY; DISEASE MODELS, ANIMAL; GAMMA-MSH; KNEE JOINT; MACROPHAGES; MALE; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELANOCORTIN, TYPE 3; RECEPTORS, CORTICOTROPIN; REPRODUCIBILITY OF RESULTS; URIC ACID;

EID: 0036822278     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10526     Document Type: Article

References (51)

1. McCarty DJ, Kohn NN, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: "the pseudogout syndrome." 1. Clinical aspects. Ann Intern Med 1962;56:711-37.
2. Dieppe PA, Crocker PR, Corke CF, Doyle DV, Huskisson EC, Willoughby DA. Synovial fluid crystals. QJM 1979;48:533-53.
3. Getting SJ, Perretti M. Arthritic diseases: melanocortin type 3 receptor agonists as potential therapeutics. Curr Opin Investig Drugs 2001;2:1064-9.
4. Terkeltaub R. Gout: crystal-induced inflammation. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press; 1992. p. 977-81.
5. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989;32:1443-52.
6. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991;34:894-903.
7. Di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor a from human blood monocytes and synovial cells: cytokine MRNA and protein kinetics, and cellular distribution. J Clin Invest 1991;87:1375-81.
8. Wolach B, Gotfried M, Jedeikin A, Lishner M, Brossi A, Ravid M. Colchicine analogues: effect on amyloidogenesis in a murine model and, in vitro, on polymorphonuclear leukocytes. Eur J Clin Invest 1992;22:630-4.
9. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
10. Hench PS, Kendall EC, Slocumb CH, Polley HE. The effect of the adrenal cortex (17-hydroxy-11-dehydrocortisone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis: preliminary report. Proc Staff Meet Mayo Clin 1949;24:181-97.
11. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
12. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696-9.
13. Brandt KD, Schumacher HR Jr. Osteoarthritis and crystal deposition diseases. Curr Opin Rheumatol 1994;6:429-32.
14. O'Donohue TL, Dorsa DM. The opiomelanotropinergic neuronal and endocrine systems. Peptides 1982;3:353-95.
15. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Immunol Today 1997;18:140-5.
16. Wikberg JES. Melanocortin receptors: perspectives for novel drugs. Eur J Pharmacol 1999;375:295-310.
17. Tatro JB. Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides. Neuroimmunomodulation 1996;3:259-84.
18. Wikberg JES, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, et al. New aspects on the melanocortins and their receptors. Pharmacol Res 2000;42:393-420.
19. Getting SJ, Gibbs L, Clark AJ, Flower RJ, Perretti M. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 1999;162:7446-53.
20. Getting SJ, Perretti M. Melanocortin receptor type 3 as a novel target for anti-inflammatory therapy. Drugs News & Perspect 2000;13:19-27.
21. Getting SJ, Allcock GH, Flower R, Perretti M. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J Leukoc Biol 2001;69:98-104.
22. Roberge CJ, de Medicis R, Dayer JM, Rola-Pleszczynski M, Naccache PH, Poubelle PE. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol 1994;152:5485-94.
23. Yang Y, Leech M, Hutchinson P, Holdsworth SR, Morand EF. Antiinflammatory effect of lipocortin 1 in experimental arthritis. Inflammation 1997;21:583-96.
24. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165-8.
25. Perretti M, Christian H, Wheller SK, Aiello I, Mugridge KG, Morris JF, et al. Annexin I is stored within gelatinase granules of human neutrophil and mobilized on the cell surface upon adhesion but not phagocytosis. Cell Biol Int 2000;24:163-74.
26. Berry DA, Lindgren BW. Statistics: theory and methods. Pacific Grove (CA): Brooks/Cole Publishing; 1990.
27. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961;54:452-60.
28. Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233:652-4.
29. Harris JG, Flower RJ, Perretti M. Endogenous corticosteroids mediate the neutrophilia caused by platelet-activating factor in the mouse. Eur J Pharmacol 1995;283:9-18.
30. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, et al. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci U S A 1993;90:8856-60.
31. Gutman AB, Yu TF. Effects of ACTH in gout. Am J Med 1950;9:24-30.
32. Buckingham JC, Smith T, Loxley HD. The control of ACTH secretion. In: James BH, editor. Comprehensive endocrinology: the adrenal cortex. New York: Raven Press; 1992. p. 132-58.
33. Buckingham JC. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1. Br J Pharmacol 1996;118:1-19.
34. Dieppe PA, Crocker PR, Corke CF, Doyle DV, Huskisson EC, Willoughby DA. Synovial fluid crystals. QJM 1979;48:533-53.
35. Getting SJ, Flower RJ, Parente L, de Medicis R, Lussier A, Woliztky BA, et al. Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins. J Pharmacol Exp Ther 1997;283:123-30.
36. Van Arman CG, Carlson RP, Risley EA, Thomas RH, Nuss GW. Inhibitory effects of indomethacin, aspirin and certain other drugs on inflammations induced in rat and dog by carrageenan, sodium urate and ellagic acid. J Pharmacol Exp Ther 1970;175:459-68.
37. Pelegri C, Franch A, Castellote C, Castell M. Immunohistochemical changes in synovial tissue during the course of adjuvant arthritis. J Rheumatol 1995;22:124-32.
38. Griffiths RJ, Li SW, Wood BE, Blackham A. A comparison of the anti-inflammatory activity of selective 5-lipoxygenase inhibitors with dexamethasone and colchicine in a model of zymosan induced inflammation in the rat knee joint and peritoneal cavity. Agents Actions 1991;32:312-20.
39. Chang DM, Baptiste P, Schur PH. The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 1990;17:1148-57.
40. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248-51.
41. Boston BA, Cone RD. Characterization of melanocortin receptor subtype expression in murine adipose tissue and in the 3T3-L1 cell line. Endocrinology 1996;137:2043-50.
42. Peck R. Neuropeptides modulating macrophage function. Ann N Y Acad Sci 1987;496:264-70.
43. Ichinose M, Sawada M, Maeno T. Suppression of phagocytosis by adrenocorticotropic hormone in murine peritoneal macrophages. Immunol Lett 1994;42:161-5.
44. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis: stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987;138:3213-8.
45. Matsukawa A, Yoshimura T, Maeda T, Takahashi T, Ohkawara S, Yoshinaga M. Analysis of the cytokine network among tumor necrosis factor α, interleukin-1β, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998;78:559-69.
46. Terkeltaub R, Baird S, Sears P, Santiago R, Boisvert W. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal-induced gouty synovitis. Arthritis Rheum 1998;41:900-9.
47. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-50.
48. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174-9.
49. Labbe O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M. Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry 1994;33:4543-9.
50. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000;26:97-102.
51. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000;141:3518-21.